Target Therapy on Tumors in HER2-positive Breast Cancer Patients Boosts Longevity

Targeted therapy on tumors in cases of HER2-positive breast cancer is more effective , according to experts.

Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Center, insisted Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive.

Potential Target To Stop Breast-Cancer Metastasis Identified
Researchers at the University of North Carolina at Chapel Hill School of Medicine have found a potential target to stop the most deadly part of breast-cancer-metastasis.

He noted that the patients undergoing combination targeted therapy had a four-month survival advantage over those who took lapatinib alone.

She said: "This is the first time that a pair of targeted therapies has been shown to be superior to any intervention that paired a targeted therapy with a hormonal or chemotherapy based approach."

As part of the study, a large, Phase III clinical trial was conducted.

Powerful Anti-breast-cancer Pill on the Anvil
The US Food and Drug Administration (FDA) has granted marketing approval to pharmaceutical giant GlaxoSmithKline for its breast cancer pill Tykerb

As part of the trial, the investigators randomized 296 patients with metastatic breast cancer to receive either lapatinib (also known as Tykerb) alone or lapatinib plus trastuzumab (Herceptin) once a day.

All participants had metastatic disease that had continued to spread even after treatments with several interventions that included trastuzumab plus chemotherapy.

Role Of Estrogen In Breast-Cancer
Scientists have been wondering how estrogen -dependent breast-cancer cells grow and spread rapidly

Trastuzumab blocks part of the HER2 growth factor that appears on the surface of some breast cancer cells while lapatinib binds to a second growth factor, EGFR, and part of HER2 that sits below the cell surface.

Clackwell explained: "It's sort of a double whammy, disabling the HER2 protein in two places instead of one."

Estrogen-derived Drug Holds Promise to Treat Breast Cancer
A study conducted on mice has found that an estrogen-derived drug may hold a promising treatment for breast cancer and breast cancer metastases to bone.

The study noted that the median overall survival following treatment with lapatinib plus trastuzumab was 60.7 weeks compared to 41.4 weeks for those who took only lapatinib.

Source-ANI
TRI